KYMR (Kymera Therapeutics, Inc.) Earnings per share for the last four quarters

Kymera Therapeutics (KYMR) relies on the development of protein degradation methods and is currently in the clinical testing phase with no current sales. The YoY ttm net income per share growth visualizes profit dynamics, where -0.70 captures the current value of the indicator. Prospects are driven by colossal demand for targeted oncology and strict adherence to green chemistry principles in the creation of new drugs.
Kymera Therapeutics, Inc. - analytical breakdowns and key metrics (KYMR)

This indicator measures the annual change in net income per share over the last 12 months, allowing investors to filter out short-term fluctuations and assess the real business momentum via the EPS TTM YoY metric. The current value of -0.70 reflects the financial performance of Kymera Therapeutics (KYMR) during the implementation of its AI platform for creating innovative targeted protein degradation drugs.